B Introduction: b Pembrolizumab (pembro) was originally approved by the FDA for the treatment of R/R cHL and R/R PMBCL at 200 mg every 3 weeks (Q3W). Treatment-related AEs occurred in 24 pts (40%) with R/R cHL and 2 (33.3%) with R/R PMBCL; grade >=3 treatme...
Introduction: 介绍 Administration of 400 mg pembrolizumab every six weeks (400 mg Q6W) has been approved based on the results of simulated pharmacokinetic (PK) modeling and exposure–response analyses. However, the safety of switching dosage from 200 mg every three weeks (Q3W) to 400 mg Q6W ...
Pembrolizumab is given as an infusion into a vein, usually once every 3 to 6 weeks. A healthcare provider will give you this injection. This medicine must be given slowly over 30 minutes. You will need frequent medical tests to help your doctor determine if it is safe for you to keep ...
200 mg IV every 3 weeks OR 400 mg every 6 weeks Continue until disease recurrence, unacceptable toxicity, or for up to 12 months in patients without disease recurrence Non-Small Cell Lung Cancer Single-agent First-line treatment of patients with stage III non-small cell lung cancer (NSCLC),...
Adult individuals with cervical cancer: 200 mg every 3 weeks or 400 mg every 6 weeks; administer Keytruda prior to chemotherapy with or without bevacizumab when given on the same day; until disease progression, unacceptable toxicity, or for Keytruda, up to 24 months ...
The study included 35 patients with BCG-unresponsive carcinoma in situ with or without concurrent Ta or T1 disease. Patients were treated with CG0070 at a dose of 1 x 1012 vp plus 400 mg of intravenous pembrolizumab every 6 weeks. CG0070 was given every week for...
every 6 weeks until the surgery, and then every 12 weeks afterward. FDG-PET scans were repeated at weeks 6 and 48. Tumor samples were collected at baseline, day 8 and day 15, followed by complete resection at week 6. A proportion of patients underwent surgery at week 12, before a...
locally advanced or metastatic Urothelial Carcinoma, MSI-H or dMMR Cancer, MSI-H or dMMR CRC, MSI-H or dMMR Endometrial Carcinoma, Esophageal Cancer, Cervical Cancer, HCC, MCC, TMB-H Cancer, or cSCC 200 mg every 3 weeks* or 400 mg every 6 weeks* Until disease progression, unacceptable...
Tumor response was assessed by radiographic imaging 9 weeks after treatment start, then every 6 weeks for the first year and every 9 weeks thereafter. Response was confirmed by repeated radiographic assessment 4 or more weeks from the first documentation of response. The primary end point was ORR...
A total of 151 study participants were randomized 1:1 to receive 25 mg of intravenous (IV) quavonlimab every 6 weeks for up to 18 cycles in combination with IV pembrolizumab administered at 400 mg for up to 18 cycles (arm F; n = 111) or IV quavonlimab alone at 25 mg for up ...